Sobieraj DM, Martinez BK, Hernandez AV, et al. - Through this systematic review and meta-analysis, researchers analyzed individuals 65 years and older with major depressive disorder (MDD), to evaluate the adverse impacts of pharmacologic antidepressants. Comparisons were performed for selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), bupropion, mirtazapine, trazodone, vilazodone, or vortioxetine vs another antidepressant, placebo, or nonpharmacologic therapy. A statistically greater number of overall adverse events were reported in correlation with treatment of the acute phase of MDD with SNRIs, but not with SSRIs, compared with placebo, in patients 65 years of age or older with MDD. In addition, a greater number of study withdrawals attributable to adverse events happened due to treatment with SSRIs and SNRIs vs placebo. With duloxetine, an increase in the falls was documented, which as an outcome was underreported in the literature.